Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome
NCT05604859Phase 4Unknown
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of methylprednisolone injection, intravenous immunoglobulin G, tocilizumab and low molecular weight heparin calcium in severe fever with thrombocytopenia syndrome (SFTS) (4 arms). Primary endpoint: 28-day survival rate. Status: unknown.
02
Drugs
methylprednisolone injectionintravenous immunoglobulin Gtocilizumablow molecular weight heparin calcium
03
Conditions
severe fever with thrombocytopenia syndrome (SFTS)
Beyond the preview
Go deeper on NCT05604859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604859.